Positions

Overview

  • Graduate of Duke University undergraduate and Chapel Hill Medical School. Completed internship/residency at UAB followed by fellowship at UAB. Currently Professor of Medicine with a focused interest in education, clinical investigation in head and neck cancer and breast cancer, and quality metrics for patient care.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2018 Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.JAMA Oncology2018
    2018 First-Line Treatment of Widely Metastatic BRAF-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition.Journal of the National Comprehensive Cancer Network.  16:1166-1170. 2018
    2018 LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.Breast Cancer Research and Treatment.  171:637-648. 2018
    2017 Implementation and utilization of the molecular tumor board to guide precision medicine.Oncotarget.  8:57845-57854. 2017
    2017 NCCN Guidelines Insights: Antiemesis, Version 2.2017.Journal of the National Comprehensive Cancer Network.  15:883-893. 2017
    2017 Implementation and utilization of the molecular tumor board to guide precision medicine.Oncotarget2017
    2016 A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma.Clinical Colorectal Cancer.  15:337-344.e2. 2016
    2016 Long-term results of a phase I/II trial of the addition of celecoxib to chemoradiotherapy for locally advanced or recurrent squamous cell carcinoma of the head-and-neckJournal of Radiation Oncology.  5:363-369. 2016
    2016 Induction chemotherapy for head and neck cancer: is there still a role?Future Oncology.  12:1595-1608. 2016
    2015 Unique presentation of blastic plasmacytoid dendritic cell neoplasm: a single-center experience and literature review.Hematological Oncology.  33:206-211. 2015
    2015 Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer.Clinical Cancer Research.  21:3658-3666. 2015
    2015 Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors.Annals of Oncology.  26:1481-1487. 2015
    2014 Assessment of erlotinib as adjuvant chemoprevention in high-risk head and neck cancer patients.Annals of Surgical Oncology.  21:4263-4269. 2014
    2014 A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007.Breast Cancer Research and Treatment.  148:99-106. 2014
    2014 African Americans with oropharyngeal carcinoma have significantly poorer outcomes despite similar rates of human papillomavirus-mediated carcinogenesis.Human Pathology.  45:310-319. 2014
    2013 Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.Clinical Cancer Research.  19:5505-5512. 2013
    2013 Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma.International Journal of Radiation Oncology - Biology - Physics.  85:1275-1281. 2013
    2013 Locoregional failure and the risk of distant metastasis after modern radiotherapy for head and neck cancer.Head & neck surgery.  35:381-387. 2013
    2012 Prognostic significance of thyroid or cricoid cartilage invasion in laryngeal or hypopharyngeal cancer treated with organ preserving strategies.Radiation Oncology.  7:219. 2012
    2012 Chemotherapy-resistant metastatic breast cancer.Current Treatment Options in Oncology.  13:263-275. 2012
    2012 By the pricking of my thumbs, something wicked this way comes: sporadic cancers versus eponymous hereditary cancer predisposition syndromes.Journal of the National Comprehensive Cancer Network.  10:7-13. 2012
    2011 Impact of average weekly dose of radiation during radiotherapy alone or chemoradiotherapy in head and neck cancer.Head & neck surgery.  33:1551-1556. 2011
    2011 Long-term follow-up of dose-dense neoadjuvant chemotherapy in patients with stage II/III breast cancer.Journal of Clinical Oncology.  29:e11048. 2011
    2010 Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.Clinical Breast Cancer.  10:275-280. 2010
    2010 Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers.Clinical Cancer Research.  16:1924-1937. 2010
    2009 Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer.International Journal of Radiation Oncology - Biology - Physics.  73:410-415. 2009
    2009 Breast cancer: Clinical Practice Guidelines in Oncology™Journal of the National Comprehensive Cancer Network.  7:122-192. 2009
    2009 Cancer of the tonsil presenting as central nervous system metastasis: A case report.Head & neck surgery.  31:127-130. 2009
    2008 Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment.International Journal of Radiation Oncology - Biology - Physics.  71:676-681. 2008
    2008 NCCN Task Force Report: breast cancer in the older woman.Journal of the National Comprehensive Cancer Network.  6 Suppl 4:S1-25. 2008
    2007 Invasive breast cancer.Journal of the National Comprehensive Cancer Network.  5:246-312. 2007
    2006 Safety and effectiveness of dose dense neoadjuvant chemotherapy in patients with stage II/III breast cancer.Journal of Clinical Oncology.  24:10622. 2006
    2006 Genetic/familial high-risk assessment: breast and ovarian.Journal of the National Comprehensive Cancer Network.  4:156-176. 2006
    2005 Breast cancer.Journal of the National Comprehensive Cancer Network.  3:238-289. 2005
    2004 Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.Journal of Clinical Oncology.  22:2856-2864. 2004
    2004 Improving the effectiveness of adjuvant psychological treatment for women with breast cancer: the feasibility of providing online support.PSYCHO-ONCOLOGY.  13:281-292. 2004
    2003 Docetaxel with concurrent radiotherapy in head and neck cancer.Seminars in Oncology.  30:89-93. 2003
    2002 Management of a patient with HIV infection-induced anemia and thrombocytopenia who presented with thrombotic thrombocytopenic purpura.American Journal of Hematology.  69:228-231. 2002
    2000 NCCN Practice Guidelines for Breast Cancer.Oncology.  14:33-49. 2000
    1999 Update: NCCN practice guidelines for the treatment of breast cancer. National Comprehensive Cancer Network.Oncology.  13:41-66. 1999
    1997 Targeted expression of a dominant negative epidermal growth factor receptor in the mammary gland of transgenic mice inhibits pubertal mammary duct development.Molecular Endocrinology -Baltimore-.  11:1766-1781. 1997
    1997 Targeted expression of a dominant negative epidermal growth factor receptor in the mammary gland of transgenic mice inhibits pubertal mammary duct developmentMolecular Endocrinology -Baltimore-.  11:1765-1781. 1997
    1995 Signal transduction by a CD16/CD7/Jak2 fusion protein.Journal of Biological Chemistry.  270:18420-18427. 1995
    1994 Human immunodeficiency virus 1 Tat stimulates transcription of the transforming growth factor alpha gene in an epidermal growth factor-dependent manner.Cell Growth and Differentiation.  5:87-93. 1994
    1987 17 beta-estradiol acts directly on the clonal osteoblastic cell line UMR106.Proceedings of the National Academy of Sciences.  84:6267-6271. 1987

    Research Overview

  • Head and Neck Cancer Breast Cancer GU cancer Sarcoma
  • Principal Investigator On

  • Private Grant  awarded by IOVANCE BIOTHERAPEUTICS INC. 2018 - 2023
  • Private Grant  awarded by ASTEX PHARMACEUTICALS 2018 - 2023
  • Private Grant  awarded by DYNAVAX TECHNOLOGIES CORPORATION 2017 - 2022
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2016 - 2021
  • Private Grant  awarded by MERCK & COMPANY, INC. 2017 - 2021
  • Private Grant  awarded by ACERTA PHARMA B.V. 2017 - 2020
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2017 - 2020
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2015 - 2020
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2015 - 2020
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW 2018 - 2019
  • Private Grant  awarded by ALTOR BIOSCIENCE CORPORATION 2017 - 2019
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2011 - 2017
  • A Phase II Study Evaluating the Efficacy and Tolerability of Everolimus (RAD001) in Combination with Trastuzumab and Vinorelbine in the Treatment of Progressive HER2-Positive Breast Cancer Brain Metastases  awarded by University of North Carolina at Chapel Hill 2012 - 2017
  • Private Grant  awarded by EXELIXIS, INC. 2009 - 2015
  • Private Grant  awarded by Genentech 2009 - 2014
  • Private Grant  awarded by ONCONOVA THERAPEUTICS 2013 - 2014
  • Private Grant  awarded by ONCOLYTICS BIOTECH 2011 - 2014
  • Private Grant  awarded by ONCOTHYREON, INC. 2011 - 2014
  • Private Grant  awarded by ONCOTHYREON, INC. 2011 - 2013
  • UAB 1018/TBCRC 011; Bicalutamide for the Treatment of Androgen Receptor Positive (AR(+)), Estrogen Receptor Negative, Progesterone Receptor Negative (ER(-)/PR(-)), Metastatic Breast Cancer Patients: A Phase II Feasibility Study  awarded by SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH 2011 - 2013
  • Private Grant  awarded by VIVENTIA BIO, INC. 2006 - 2011
  • Investigator On

  • Private Grant  awarded by ASTRAZENECA AB 2018 - 2023
  • Private Grant  awarded by CLOVIS ONCOLOGY 2017 - 2022
  • Private Grant  awarded by CLOVIS ONCOLOGY 2017 - 2022
  • Private Grant  awarded by AMGEN, INC. 2016 - 2021
  • Private Grant  awarded by REXAHN PHARMACEUTICALS, INC. 2016 - 2021
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2012 - 2020
  • Phase 1, Open-Label Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cetuximab-IRDye800 as an Optical Imaging Agent to Detect Cancer during Surgical Procedures  awarded by Stanford University 2015 - 2020
  • Phase I, Open-label Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Head and Neck Cancer During Surgical Procedures  awarded by Stanford University 2015 - 2020
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2015 - 2020
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2015 - 2019
  • TBCRC030 - A Randomized Phase II Study of Preoperative Cisplatin versus Paclitaxel in Patients with Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker  awarded by Johns Hopkins University 2014 - 2019
  • UAB 1764:The Targeted Agent and Profiling Utilization Registry (TAPUR) Study  awarded by American Society of Clinical Oncology 2017 - 2019
  • UAB 1326: A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-Amplified but HER2 Mutant Breast Cancer  awarded by Washington University 2013 - 2019
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2017 - 2019
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2014 - 2019
  • TBCRC 026/UAB 1367: A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) with Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients with Primary Operable HER2-Positive Breast Cancer (ML28190)  awarded by Johns Hopkins University 2014 - 2019
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2017 - 2019
  • UAB 1174: Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2  awarded by QUANTUM LEAP HEALTH CARE 2012 - 2019
  • Private Grant  awarded by CELLDEX THERAPEUTICS, INC. 2014 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2015 - 2019
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2014 - 2019
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2013 - 2019
  • Private Grant  awarded by ELI LILLY AND COMPANY 2016 - 2019
  • TBCRC 036 (UAB 1366): Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab + Pertuzumab, or Combination Trastuzumab + Lapatinib  awarded by Lineberger Comprehensive Care Center 2014 - 2019
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2013 - 2018
  • Biomarkers for Detection of Renal Cell Carcinoma  awarded by American Cancer Society, Inc. 2017 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2013 - 2018
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2017 - 2018
  • Southwest Oncology Group Purchase Service Agreement  awarded by SOUTHWEST ONCOLOGY GROUP 2013 - 2018
  • Southwest Oncology Group Clinical Trials Initiative Purchase Service Agreement  awarded by SOUTHWEST ONCOLOGY GROUP 2013 - 2018
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2014 - 2017
  • Private Grant  awarded by Novartis Pharma AG 2014 - 2017
  • Private Grant  awarded by REXAHN PHARMACEUTICALS, INC. 2016 - 2017
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2012 - 2017
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2015 - 2017
  • Private Grant  awarded by OBI PHARMA, INC. 2012 - 2017
  • Private Grant  awarded by Genentech 2011 - 2017
  • Private Grant  awarded by Sanofi US Services Inc 2012 - 2017
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2014 - 2016
  • Private Grant  awarded by SUCAMPO PHARMACEUTICALS 2016
  • Private Grant  awarded by NOVADAQ TECHNOLOGIES, INC. 2015 - 2016
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2011 - 2016
  • Private Grant  awarded by INCYTE CORPORATION 2013 - 2016
  • Private Grant  awarded by PNP THERAPEUTICS, INC. 2011 - 2016
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2011 - 2015
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2011 - 2015
  • Private Grant  awarded by LICOR, INC. 2014 - 2015
  • UAB 1019/TBCRC 015: Investigation of Genetic Determinants of Capecitabine Toxicity  awarded by Johns Hopkins University 2010 - 2015
  • A Prospective Analysis of Surgery in Patients Presenting with Stage IV Breast Cancer - TBCRC 013 / UAB 0953  awarded by Johns Hopkins University 2009 - 2015
  • UAB 1018/TBCRC 011; Bicalutamide for the Treatment of Androgen Receptor Positive (AR(+), Estrogen Receptor Negative, Progesterone Receptor Negative (ER(-)/PR(-), Metastatic Breast Cancer Patients: A Phase II Feasibility Study  awarded by Johns Hopkins University 2009 - 2015
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2013 - 2015
  • Private Grant  awarded by ABBVIE INC 2014 - 2015
  • Imaging Guided Surgery using Fluorescently Labeled Cetuximab  awarded by National Cancer Institute/NIH/DHHS 2014 - 2015
  • Private Grant  awarded by Genentech 2011 - 2015
  • Private Grant  awarded by CYCLACEL LTD 2014 - 2015
  • Private Grant  awarded by NOVADAQ TECHNOLOGIES, INC. 2013 - 2015
  • UAB 1033/TBCRC 018: A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201) in Combination with Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis  awarded by Johns Hopkins University 2010 - 2015
  • Private Grant  awarded by DYNASPLINTT SYSTEM, INC. 2012 - 2015
  • Private Grant  awarded by SELEXYS 2014 - 2015
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2011 - 2015
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2012 - 2015
  • Private Grant  awarded by SYNTA PHARMACEUTICALS 2013 - 2014
  • Private Grant  awarded by WYETH PHARMACEUTICALS, INC. 2011 - 2014
  • Private Grant  awarded by ELI LILLY AND COMPANY 2013 - 2014
  • Private Grant  awarded by Genentech 2007 - 2014
  • Private Grant  awarded by MERRIMACK PHARMACEUTICALS, INC. 2013 - 2014
  • Private Grant  awarded by AVEO PHARMACEUTICALS, INC 2013 - 2014
  • Private Grant  awarded by MERRIMACK PHARMACEUTICALS, INC. 2012 - 2014
  • Private Grant  awarded by INCYTE CORPORATION 2013
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2012 - 2013
  • Education And Training

    Full Name

  • Lisle Nabell
  • Blazerid

  • lisle